James T Kearns1, Anna V Faino2, Lisa F Newcomb3, James D Brooks4, Peter R Carroll5, Atreya Dash6, William J Ellis6, Michael Fabrizio7, Martin E Gleave8, Todd M Morgan9, Peter S Nelson2, Ian M Thompson10, Andrew A Wagner11, Yingye Zheng2, Daniel W Lin6. 1. Department of Urology, University of Washington, Seattle, WA, USA. Electronic address: jkearns1@uw.edu. 2. Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 3. Department of Urology, University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 4. Stanford University, Stanford, CA, USA. 5. University of California, San Francisco, CA, USA. 6. Department of Urology, University of Washington, Seattle, WA, USA. 7. Eastern Virginia Medical School, VA, USA. 8. University of British Columbia, Vancouver, BC, Canada. 9. University of Michigan, Ann Arbor, MI, USA. 10. University of Texas Health Sciences Center at San Antonio, TX, USA. 11. Beth Israel Deaconess Medical Center, Boston, MA, USA.
Abstract
BACKGROUND: Many patients who are on active surveillance (AS) for prostate cancer will have surveillance prostate needle biopsies (PNBs) without any cancer evident. OBJECTIVE: To define the association between negative surveillance PNBs and risk of reclassification on AS. DESIGN, SETTING, AND PARTICIPANTS: All men were enrolled in the Canary Prostate Active Surveillance Study (PASS) between 2008 and 2016. Men were included if they had Gleason ≤3+4 prostate cancer and <34% core involvement ratio at diagnosis. Men were prescribed surveillance PNBs at 12 and 24 mo after diagnosis and then every 24 mo. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Reclassification was defined as an increase in Gleason grade and/or an increase in the ratio of biopsy cores to cancer to ≥34%. PNB outcomes were defined as follows: (1) no cancer on biopsy, (2) cancer without reclassification, or (3) reclassification. Kaplan-Meier and Cox proportional hazard models were performed to assess the risk of reclassification. RESULTS AND LIMITATIONS: A total of 657 men met inclusion criteria. On first surveillance PNB, 214 (32%) had no cancer, 282 (43%) had cancer but no reclassification, and 161 (25%) reclassified. Among those who did not reclassify, 313 had a second PNB. On second PNB, 120 (38%) had no cancer, 139 (44%) had cancer but no reclassification, and 54 (17%) reclassified. In a multivariable analysis, significant predictors of decreased future reclassification after the first PNB were no cancer on PNB (hazard ratio [HR]=0.50, p=0.008), lower serum prostate-specific antigen, larger prostate size, and lower body mass index. A finding of no cancer on the second PNB was also associated with significantly decreased future reclassification in a multivariable analysis (HR=0.15, p=0.003), regardless of the first PNB result. The major limitation of this study is a relatively small number of patients with long-term follow-up. CONCLUSIONS: Men who have a surveillance PNB with no evidence of cancer are significantly less likely to reclassify on AS in the PASS cohort. These findings have implications for tailoring AS protocols. PATIENT SUMMARY: Men on active surveillance for prostate cancer who have a biopsy showing no cancer are at a decreased risk of having worse disease in the future. This may have an impact on how frequently biopsies are required to be performed in the future.
BACKGROUND: Many patients who are on active surveillance (AS) for prostate cancer will have surveillance prostate needle biopsies (PNBs) without any cancer evident. OBJECTIVE: To define the association between negative surveillance PNBs and risk of reclassification on AS. DESIGN, SETTING, AND PARTICIPANTS: All men were enrolled in the Canary Prostate Active Surveillance Study (PASS) between 2008 and 2016. Men were included if they had Gleason ≤3+4 prostate cancer and <34% core involvement ratio at diagnosis. Men were prescribed surveillance PNBs at 12 and 24 mo after diagnosis and then every 24 mo. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Reclassification was defined as an increase in Gleason grade and/or an increase in the ratio of biopsy cores to cancer to ≥34%. PNB outcomes were defined as follows: (1) no cancer on biopsy, (2) cancer without reclassification, or (3) reclassification. Kaplan-Meier and Cox proportional hazard models were performed to assess the risk of reclassification. RESULTS AND LIMITATIONS: A total of 657 men met inclusion criteria. On first surveillance PNB, 214 (32%) had no cancer, 282 (43%) had cancer but no reclassification, and 161 (25%) reclassified. Among those who did not reclassify, 313 had a second PNB. On second PNB, 120 (38%) had no cancer, 139 (44%) had cancer but no reclassification, and 54 (17%) reclassified. In a multivariable analysis, significant predictors of decreased future reclassification after the first PNB were no cancer on PNB (hazard ratio [HR]=0.50, p=0.008), lower serum prostate-specific antigen, larger prostate size, and lower body mass index. A finding of no cancer on the second PNB was also associated with significantly decreased future reclassification in a multivariable analysis (HR=0.15, p=0.003), regardless of the first PNB result. The major limitation of this study is a relatively small number of patients with long-term follow-up. CONCLUSIONS: Men who have a surveillance PNB with no evidence of cancer are significantly less likely to reclassify on AS in the PASS cohort. These findings have implications for tailoring AS protocols. PATIENT SUMMARY: Men on active surveillance for prostate cancer who have a biopsy showing no cancer are at a decreased risk of having worse disease in the future. This may have an impact on how frequently biopsies are required to be performed in the future.
Authors: Aaron A Laviana; Annette M Ilg; Darlene Veruttipong; Hung-Jui Tan; Michael A Burke; Douglas R Niedzwiecki; Patrick A Kupelian; Chris R King; Michael L Steinberg; Chandan R Kundavaram; Mitchell Kamrava; Alan L Kaplan; Andrew K Moriarity; William Hsu; Daniel J A Margolis; Jim C Hu; Christopher S Saigal Journal: Cancer Date: 2015-11-02 Impact factor: 6.860
Authors: Florian M E Wagenlehner; Edgar van Oostrum; Peter Tenke; Zafer Tandogdu; Mete Çek; Magnus Grabe; Björn Wullt; Robert Pickard; Kurt G Naber; Adrian Pilatz; Wolfgang Weidner; Truls E Bjerklund-Johansen Journal: Eur Urol Date: 2012-06-12 Impact factor: 20.096
Authors: Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: Kenneth S Tseng; Patricia Landis; Jonathan I Epstein; Bruce J Trock; H Ballentine Carter Journal: J Urol Date: 2010-03-20 Impact factor: 7.450
Authors: Marc A Dall'Era; Peter C Albertsen; Christopher Bangma; Peter R Carroll; H Ballentine Carter; Matthew R Cooperberg; Stephen J Freedland; Laurence H Klotz; Christopher Parker; Mark S Soloway Journal: Eur Urol Date: 2012-06-07 Impact factor: 20.096
Authors: Scott E Eggener; Alex Mueller; Ryan K Berglund; Raj Ayyathurai; Cindy Soloway; Mark S Soloway; Robert Abouassaly; Eric A Klein; Steven J Jones; Chris Zappavigna; Larry Goldenberg; Peter T Scardino; James A Eastham; Bertrand Guillonneau Journal: J Urol Date: 2009-02-23 Impact factor: 7.450
Authors: Mufaddal M Mamawala; Karthik Rao; Patricia Landis; Jonathan I Epstein; Bruce J Trock; Jeffrey J Tosoian; Kenneth J Pienta; H Ballentine Carter Journal: BJU Int Date: 2016-08-29 Impact factor: 5.588
Authors: Lisa F Newcomb; Ian M Thompson; Hilary D Boyer; James D Brooks; Peter R Carroll; Matthew R Cooperberg; Atreya Dash; William J Ellis; Ladan Fazli; Ziding Feng; Martin E Gleave; Priya Kunju; Raymond S Lance; Jesse K McKenney; Maxwell V Meng; Marlo M Nicolas; Martin G Sanda; Jeffry Simko; Alan So; Maria S Tretiakova; Dean A Troyer; Lawrence D True; Funda Vakar-Lopez; Jeff Virgin; Andrew A Wagner; John T Wei; Yingye Zheng; Peter S Nelson; Daniel W Lin Journal: J Urol Date: 2015-08-29 Impact factor: 7.450
Authors: K Clint Cary; Janet E Cowan; Melissa Sanford; Katsuto Shinohara; Nannette Perez; June M Chan; Maxwell V Meng; Peter R Carroll Journal: Eur Urol Date: 2013-09-09 Impact factor: 20.096
Authors: Jonathan B Bloom; Graham R Hale; Samuel A Gold; Kareem N Rayn; Clayton Smith; Sherif Mehralivand; Marcin Czarniecki; Vladimir Valera; Bradford J Wood; Maria J Merino; Peter L Choyke; Howard L Parnes; Baris Turkbey; Peter A Pinto Journal: J Urol Date: 2019-01 Impact factor: 7.450
Authors: Peter S Kirk; Kehao Zhu; Yingye Zheng; Lisa F Newcomb; Jeannette M Schenk; James D Brooks; Peter R Carroll; Atreya Dash; William J Ellis; Christopher P Filson; Martin E Gleave; Michael Liss; Frances Martin; Jesse K McKenney; Todd M Morgan; Peter S Nelson; Ian M Thompson; Andrew A Wagner; Daniel W Lin; John L Gore Journal: Cancer Date: 2021-09-13 Impact factor: 6.860
Authors: Mattia Luca Piccinelli; Stefano Luzzago; Giulia Marvaso; Ekaterina Laukhtina; Noriyoshi Miura; Victor M Schuettfort; Keiichiro Mori; Alberto Colombo; Matteo Ferro; Francesco A Mistretta; Nicola Fusco; Giuseppe Petralia; Barbara A Jereczek-Fossa; Shahrokh F Shariat; Pierre I Karakiewicz; Ottavio de Cobelli; Gennaro Musi Journal: World J Urol Date: 2022-03-26 Impact factor: 3.661